On January 2, 2018 Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), reported that Dr. André Choulika, Chairman and Chief Executive Officer of Cellectis, will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 p.m. Pacific Time in the Elizabethan A/B room (Press release, Cellectis, JAN 2, 2018, View Source [SID1234522815]). A Q&A session will follow at 1:30 p.m. PT in the Sussex room. The conference will be held from January 8 to 11, 2018 at the Westin St. Francis Hotel in San Francisco, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast of Cellectis presentation and subsequent breakout session, please visit View Source A replay of the webcast will be available on Cellectis website for 90 days.